Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

导出原文传递

翻译打印收藏纠错

作者： Aroda, Vanita R. ^[1] ; Bain, Stephen C. ^[2] ; Cariou, Bertrand ^[3] ; Piletic, Milivoj ^[4] ; Rose, Ludger ^[5] ; Axelsen, Mads ^[6] ; Rowe, Everton ^[7] ; DeVries, J. Hans ^[8]

作者单位： Swansea Univ, Sch Med, Swansea, W Glam, Wales ^[1] MedStar Hlth Res Inst, Hyattsville, MD USA ^[2] Novo Nordisk, Soborg, Denmark ^[3] CHU Nantes, Inst Thorax, Nantes, France ^[4] Munster Inst Diabet Res, Munster, Germany ^[5] Novo Nordisk, Princeton, NJ USA ^[6] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands ^[7] Gen Hosp, Novo Mesto, Slovenia ^[8]

发布时间 2017-06-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览3

The lancet. Diabetes & endocrinology.

2017年5卷5期

355-366页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The lancet. Diabetes & endocrinology.

相似文献

The lancet. Diabetes & endocrinology.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The lancet. Diabetes & endocrinology.

相似文献

The lancet. Diabetes & endocrinology.

相关期刊

检索历史清除